ACRO Biomedical Co (6748.TWO) Stock Price

ACRO Biomedical Co Price

CLOSED
228.00
-12.00 (-5.13 %)
Market closed

Over the last 7 years ACRO Biomedical Co grew revenue by 12.1% annually, reaching 38.26 M TWD. For ACRO Biomedical Co, the net margin of -216.1% is up versus -232.6% a few years ago. The stock trades about 296% above its 52-week low.

ACRO Biomedical Co stock price

Access this data via the Eulerpool API

ACRO Biomedical Co business model & stock analysis

Frequently asked questions about ACRO Biomedical Co

Converted at the current exchange rate, the ACRO Biomedical Co share trades at 6.30 EUR (228.00 TWD).

No history available for ACRO Biomedical Co.

The revenue cannot currently be calculated for ACRO Biomedical Co.

The profit cannot currently be calculated for ACRO Biomedical Co.

The P/E ratio cannot be calculated for ACRO Biomedical Co at the moment.

The P/S cannot be calculated for ACRO Biomedical Co currently.

The Eulerpool Quality Score for ACRO Biomedical Co is 3/10.

The ISIN of ACRO Biomedical Co is TW0006748007. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of ACRO Biomedical Co is 6748.TWO. The ticker symbol is used to trade ACRO Biomedical Co shares on the stock exchange.

ACRO Biomedical Co paid dividends every year for the past 0 years.

ACRO Biomedical Co is assigned to the 'Health' sector.

The dividends of ACRO Biomedical Co are distributed in TWD.

Fair ValueTerminal
228.00 TWD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Taiwan
Currency
TWD
Initial public offering
Jul 27, 2021
ISIN
TW0006748007
Cusip
Y000YY101
Market capitalization
16.24 B TWDLarge Cap
52-Week Range
57.60–295.00TWD
Revenue growth (10Y) > 5%
Revenue growth (3Y) > 5 %
EBIT growth (10Y) > 5%
EBIT growth (3Y) > 5 %
Net debt < 4x EBIT
Profitable since 10Y+
EBIT Drawdown (10Y) < 50%
Return on Equity (ROE) > 15%
ROCE > 15%
Return Expectation > 10%
PEG
—
P/E ratio
P/Ee
—
P/Se
—
EV/EBIT
—
P/B Ratio
14.70
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-7.48 %
Gross Margin
48.43 %
EBIT Margin
-242.80 %
Net Margin
-216.06 %
EPS (Earnings Per Share)
-1.35 TWD
Net Debt / EBIT
—
Debt/Equity
0.03
Last updated Sep 27, 2026, 11:55 AM

ACRO Biomedical Co Peer Group

ACRO Biomedical Co FIGI

6748:TT (Taipei Stock Exchange) · BBG011W9RRN7